Shares of IGM Biosciences, Inc. (NASDAQ:IGMS - Get Free Report) have been assigned an average rating of "Reduce" from the ten analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and nine have assigned a hold recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $5.50.
IGMS has been the subject of several research reports. Jefferies Financial Group reaffirmed a "hold" rating and set a $2.00 price target (down previously from $48.00) on shares of IGM Biosciences in a research note on Friday, January 10th. Stifel Nicolaus cut shares of IGM Biosciences from a "buy" rating to a "hold" rating and cut their target price for the stock from $27.00 to $2.50 in a research report on Friday, January 10th. Truist Financial lowered their price target on shares of IGM Biosciences from $12.00 to $2.00 and set a "hold" rating on the stock in a research report on Friday, January 10th. BMO Capital Markets restated a "market perform" rating and set a $2.00 price objective (down from $21.00) on shares of IGM Biosciences in a research report on Friday, January 10th. Finally, Royal Bank of Canada lowered IGM Biosciences from an "outperform" rating to a "sector perform" rating and reduced their target price for the company from $20.00 to $1.50 in a research note on Friday, January 10th.
Get Our Latest Analysis on IGMS
IGM Biosciences Stock Performance
IGMS stock traded down $0.04 during trading on Tuesday, reaching $1.24. 124,722 shares of the company were exchanged, compared to its average volume of 339,690. IGM Biosciences has a 52-week low of $1.15 and a 52-week high of $22.50. The company has a market cap of $74.12 million, a P/E ratio of -0.34 and a beta of 0.37. The stock's 50 day moving average price is $1.40 and its 200 day moving average price is $7.86.
IGM Biosciences (NASDAQ:IGMS - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.13. IGM Biosciences had a negative return on equity of 155.42% and a negative net margin of 7,534.03%. The business had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.39 million. As a group, equities research analysts forecast that IGM Biosciences will post -3.35 EPS for the current year.
Institutional Investors Weigh In On IGM Biosciences
A number of hedge funds and other institutional investors have recently made changes to their positions in IGMS. China Universal Asset Management Co. Ltd. acquired a new stake in IGM Biosciences in the 4th quarter worth about $44,000. MetLife Investment Management LLC acquired a new stake in shares of IGM Biosciences in the third quarter worth approximately $149,000. Barclays PLC boosted its position in shares of IGM Biosciences by 48.4% in the third quarter. Barclays PLC now owns 21,554 shares of the company's stock worth $356,000 after acquiring an additional 7,027 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in IGM Biosciences in the fourth quarter valued at approximately $184,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in IGM Biosciences during the fourth quarter worth approximately $222,000. Hedge funds and other institutional investors own 42.79% of the company's stock.
IGM Biosciences Company Profile
(
Get Free ReportIGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.
Featured Articles
Before you consider IGM Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IGM Biosciences wasn't on the list.
While IGM Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
